bims-myxlip Biomed News
on Myxoid liposarcoma
Issue of 2024–11–17
three papers selected by
Laura Mannarino, Humanitas Research



  1. Lancet. 2024 Nov 12. pii: S0140-6736(24)02252-9. [Epub ahead of print]
      
    DOI:  https://doi.org/10.1016/S0140-6736(24)02252-9
  2. Expert Opin Pharmacother. 2024 Nov 13. 1-14
       INTRODUCTION: Liposarcomas are malignancies of adipocytic lineage and represent one of the most common types of soft tissue sarcomas. They encompass multiple histologies, each with unique molecular profiles. Treatment for localized disease includes resection, potentially with perioperative radiation or systemic therapy. Treatment for unresectable or metastatic disease revolves around palliative systemic therapy, for which improved therapies are urgently needed.
    AREAS COVERED: We reviewed the literature on novel therapies in clinical development for liposarcomas within the past 5 years and discuss their potential impact on future treatment strategies.
    EXPERT OPINION: Understanding of the molecular characteristics of liposarcoma subtypes has led to testing of several targeted therapies, including inhibitors of amplified gene products (CDK4 and MDM2) and upregulated proteins (XPO1). Immuno-oncology has played an increasing role in the treatment of liposarcomas, with checkpoint inhibition showing promise in dedifferentiated liposarcomas, and immune therapies targeting cancer testis antigens NY-ESO-1 and MAGE family proteins poised to become an option for myxoid/round cell liposarcomas. The search for novel agents from existing classes (tyrosine kinase inhibitors) with efficacy in liposarcoma also continues. Combination therapies as well as biomarker identification for patient selection of therapies warrant ongoing exploration.
    Keywords:  CDK4 inhibitor; Liposarcoma; MDM2 inhibitor; cancer testis antigens; cellular therapy; chromosomal amplification; immunotherapy; targeted therapy
    DOI:  https://doi.org/10.1080/14656566.2024.2427333
  3. Int J Surg Case Rep. 2024 Nov 10. pii: S2210-2612(24)01363-4. [Epub ahead of print]125 110582
       BACKGROUND: Mediastinal liposarcoma is an extremely rare malignant tumor of adipocytic differentiation, comprising less than 1 % of all liposarcomas. The majority occur in the lower extremities, with approximately 75 % of cases. Myxoid liposarcoma of the anterior mediastinum can present similarly to other thoracic pathologies.
    CASE PRESENTATION: We present the case of a 36-year-old female who presented with a 14-day history of worsening dyspnea at rest, along with swelling of the upper extremities and face. On examination, distended neck and anterior chest veins were observed. Imaging studies revealed a large anterior mediastinal mass causing extrinsic compression of adjacent structures and a mediastinal shift to the right. Following stabilization, the patient underwent successful surgical resection of the mass.
    DISCUSSION: Myxomatous liposarcoma is a very rare tumor located in the mediastinum that presents with symptoms resembling other lung diseases. Common complaints include chest pain, shortness of breath, and difficulty swallowing. Diagnosis is largely based on radiological imaging or histological examination after surgery. The primary treatment involves surgery and occasionally chemotherapy. Prompt diagnosis and timely treatment enhance the likelihood of positive outcomes for those affected.
    CONCLUSION: This case underscores the importance of considering mediastinal liposarcoma in the differential diagnosis of patients presenting with chronic cough and unquantified weight loss, especially when symptoms escalate into conditions such as superior vena cava syndrome. Early detection and timely treatment are crucial for improving outcomes. This case contributes valuable insight, particularly relevant to managing complex tumors in resource-limited settings.
    Keywords:  Anterior mediastinal mass; Case report; Clamshell thoracotomy; Myxoid liposarcoma
    DOI:  https://doi.org/10.1016/j.ijscr.2024.110582